Rosuvastatin: A review of its effect on atherosclerosis

American Journal of Cardiovascular Drugs

Volumn 8, Issue 2, 2008, Pages 127-146

  Keating, Gillian M ^a,b   Robinson, Dean M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Evaluations; Atherosclerosis, prevention; HMG CoA reductase inhibitors, therapeutic use; Rosuvastatin, pharmacodynamics; Rosuvastatin, pharmacokinetics; Rosuvastatin, therapeutic use

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CYCLOSPORIN A; DIGOXIN; EZETIMIBE; FENOFIBRATE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; ORGANIC ANION TRANSPORTER 2; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRALGIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG UPTAKE; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIVER CELL; METABOLIC SYNDROME X; MYALGIA; MYOPATHY; NAUSEA; NONHUMAN; PHARYNGITIS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RACE DIFFERENCE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; WEAKNESS;

EID: 42449146213     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256589     Document Type: Review

References (104)

1. National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002 Dec 17; 106 (25): 3143-421
2. Lauer MS. Primary prevention of atherosclerotic cardiovasular disease: the high public burden of low individual risk. JAMA 2007 Mar 28; 297 (12): 1376-8
3. Chu B, Hatsukami TS, Polissar NL, et al. Determination of carotid artery atherosclerotic lesion type and distribution in hypercholesterolemic patients with moderate carotid stenosis using noninvasive magnetic resonance imaging. Stroke 2004 Nov; 35 (11): 2444-8
4. Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2004; 4 (2): 117-38
5. AstraZeneca. Crestor® now indicated to slow the progression of atherosclerosis in patients with elevated cholesterol [media release]. Available from URL: http://www.astrazeneca-us.com [Accessed 2007 Nov 19]
6. Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering: are they clinically relevant? Eur Heart J 2003 Feb; 24 (3): 225-48
7. Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells [abstract no. MoP29:W6]. Atherosclerosis 2000; 157 Suppl.: 41
8. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004 May; 75 (5): 455-63
9. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004 Aug; 76 (2): 167-77
10. Brown CDA, Windass A, Bleasby K, et al. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C [abstract no. 166]. Atheroscler Suppl 2001; 2 (2): 88
11. Kapur NK. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Rev Cardiovasc Ther 2007 Mar; 5 (2): 161-75
12. Smith G, Davidson R, Bloor S, et al. Pharmacological properties of ZD4522: a new HMG-CoA reductase inhibitor [abstract no. MoP20:W6]. Atherosclerosis 2000; 151: 39
13. Holdgate GA, Ward WHJ, McTaggart F. Molecular mechanism for inhibition of 3-Rosuvastahydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 2003; 31 Pt 3 (Pt 3): 528-31
14. Schaefer JR, Schweer H, Ikewaki K, et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 1999; 144 (1): 177-84
15. Ooi EMM, Watts GF, Nestel PJ, et al. Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. J Clin Endocrinol Metab 2008 Feb; 93 (2): 430-7
16. Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002 Dec; 144 (6): 1036-43
17. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002 Feb 1; 89 (3): 268-75
18. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003 Jul 15; 92 (2): 152-60
19. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002 Dec; 144 (6): 1044-51
20. Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001; 8 (6): 383-90
21. Schneck DW, Knopp RH, Ballantyne CM, et al. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003 Jan 1; 91 (1): 33-41
22. Clearfield MB, Amerena J, Bassand J-P, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia: Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials 2006 Dec 21; 7: 35
23. Leiter LA, Rosenson RS, Stein E, et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007 Oct; 194 (2): e154-64
24. Betteridge DJ, Gibson JM, on behalf of the ANDROMEDA Study Investigators. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med 2007 May; 24 (5): 541-9
25. Stalenhoef AFH, Ballantyne CM, Sarti C, et al. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. Eur Heart J 2005; 26 (24): 2664-72
26. Ferdinand KC, Clark LT, Watson KE, et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol 2006 Jan 15; 97 (2): 229-35
27. Lloret R, Yčas J, Stein M, et al. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol 2006 Sep 15; 98 (6): 768-73
28. Deedwania PC, Gupta M, Stein M, et al. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol 2007 Jun 1; 99 (11): 1538-43
29. Insull Jr W, Ghali JK, Hassman DR, et al. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR Trial. Mayo Clin Proc 2007 May; 82 (5): 543-50
30. Faergeman O, Sosef F, Duffield E. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in high-risk patients: results from the ECLIPSE study [abstract no. Th-P16:394]. Atherosclerosis 2006 Jun; 7 (3 Suppl.): 580
31. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004 Apr; 147 (4): 705-12
32. Ballantyne CM, Bertolami M, Hernandez Garcia HR, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J 2006 May; 151 (5): 975.e1-9
33. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998 Oct; 19: 1434-503
34. Bots AFE, Kastelein JJP, on behalf of the DISCOVERY Netherlands Investigators. Achieving lipid goals in real life: the Dutch DISCOVERY study. Int J Clin Pract 2005 Dec; 59 (12): 1387-94
35. Binbrek AS, Elis A, Al-Zaibag M, et al. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: a randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study). Curr Ther Res Clin Exp 2006 Jan/Feb; 67 (1): 21-43
36. Fonseca FAH, Ruiz A, Cardona-Muñoz EG, et al. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value - an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr Med Res Opin 2005 Aug; 21 (8): 1307-15
37. Middleton A, Fuat A. Achieving lipid goals in real life: the DISCOVERY-UK study. Br J Cardiol 2006; 13 (1): 72-6
38. Strandberg TE, Feely J, Sigurdsson EL. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin Ther 2004 Nov; 26 (11): 1821-33
39. Zhu J-R, Tomlinson B, Ro YM, et al. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk cardiovascular disease (DISCOVERY-Asia study). Curr Med Res Opin 2007; 23 (12): 3055-68
40. Middleton A, Binbrek AS, Fonseca FAH, et al. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Curr Med Res Opin 2006 Jun; 22 (6): 1181-91
41. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003 Dec; 10 Suppl. 1: S1-S78
42. Crouse III JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007 Mar 28; 297 (12): 1344-53
43. Underhill HR, Yuan C, Zhao X-Q, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008 Mar; 155 (3): 584.e1-8
44. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 Apr 5; 295 (13): 1556-65
45. Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 2004; 26 (9): 1388-99
46. LaRosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001 Aug 1; 88: 291-3
47. ter Avest E, Abbink EJ, Holewijn S, et al. Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipiaemia (FCH). Curr Med Res Opin 2005 Sep; 21 (9): 1469-76
48. Resch U, Tatzber F, Budinsky A, et al. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006 Mar; 61 (3): 262-74
49. Link A, Ayadhi T, Böhm M, et al. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006 Dec; 27 (24): 2945-55
50. Lu T-M, Ding Y-A, Leu H-B, et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004 Jul 15; 94 (2): 157-61
51. Bergheanu SC, Van Tol A, Dallinga-Thie GM, et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin 2007; 23 (9): 2235-40
52. van Oostrom AJHHM, Plokker HWM, Van Asbeck BS, et al. Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis. Atherosclerosis 2006 Apr 1; 185 (2): 331-9
53. Serebruany VL, Miller M, Pokov AN, et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 Inhibition by Statins [PARIS] study). Am J Cardiol 2006 May 1; 97 (9): 1332-6
54. Schäfer K, Kaiser K, Konstantinides S. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost 2005 Jan; 93 (1): 145-52
55. Werner N, Priller J, Laufs U, et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition. Arterioscler Thromb Vasc Biol 2002 Oct 1; 22 (10): 1567-72
56. Furman C, Copin C, Kandoussi M, et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 2004 May; 174 (1): 93-8
57. Chen J, Li D, Schaefer RF, et al. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. J Cardiovasc Pharmacol 2004 Oct; 44 (4): 446-52
58. Simonson SG, Martin PD, Mitchell PD, et al. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 2005 Aug; 45 (8): 927-34
59. Martin PD, Warwick MJ, Dane AL, et al. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther 2003 Aug; 25 (8): 2215-24
60. Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003; 25 (10): 2553-63
61. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002 Nov; 54 (5): 472-7
62. AstraZeneca. Crestor® (rosuvastatin calcium): US prescribing information [online]. Available from URL: http://rosuvastatininformation.com [Accessed 2007 Nov 19]
63. Nezasa K-I, Higaki K, Matsumura T, et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 2002 Nov; 30 (11): 1158-63
64. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy volunteers. Clin Ther 2003 Nov; 25 (11): 2822-35
65. Schuster H. Rosuvastatin: a highly effective new 3-hydroxy-3- methylglutaryl coenzyme A reductaase inhibitor. Review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology 2003; 99: 126-39
66. McCormick AD, McKillop D, Butters CJ, et al. ZD452: an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions. Metabolic studies in human in vitro systems [abstract no. 46]. J Clin Pharmacol 2000 Sep; 40 (9): 1055
67. Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002 Oct; 42 (10): 1116-21
68. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005 Oct; 78 (4): 330-41
69. AstraZeneca. Crestor® (rosuvastatin): European prescribing information [online]. Available from URL: http://rosuvastatininformation.com [Accessed 2007 Oct 1]
70. Cooper KJ, Martin PD, Dane AL, et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003 May; 59 (1): 51-6
71. Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvstatin in healthy subjects. Br J Clin Pharmacol 2003; 55 (1): 94-9
72. Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003 Apr; 73 (4): 322-9
73. Cooper KJ, Martin PD, Dane AL, et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002 Nov; 58 (8): 527-31
74. Martin PD, Dane AL, Schneck DW, et al. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003 Feb; 25 (2): 459-71
75. Kosoglou T, Statkevich P, Yang B, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004; 20 (8): 1185-95
76. Martin PD, Kemp J, Dane AL, et al. No effect of rosuvatatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 2002 Dec; 42 (12): 1352-7
77. Simonson SG, Martin PD, Warwick MJ, et al. The effect of rosuvastatin on oestrogen and progrestin pharamcokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol 2004 Mar; 57 (3): 279-86
78. Evans GW, Raichlen JS, Bots ML, et al. Rosuvastatin treatment in carotid atherosclerosis: effect of Framingham risk factors and baseline intima-media thickness in the METEOR trial [abstract no. 3730]. Circulation 2007; 116 Suppl. II: 848
79. Bots ML, Raichlen JS, Evans GW, et al. Rosuvastatin reduces progression of carotid atherosclerosis within 12 months of treatment: the METEOR trial [abstract no. 194]. Circulation 2007; 116 Suppl. II: 17
80. Shepherd J, Vidt DG, Miller E, et al. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007; 107 (4): 433-43
81. Kasliwal R, Wilton LV, Cornelius V, et al. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11 680 patients. Drug Saf 2007; 30 (2): 157-70
82. McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48 000 initiators of statin therapy. Pharmacoepidemiol Drug Saf 2006 Jul; 15 (7): 444-53
83. Goettsch WG, Heintjes EM, Kastelein JJP, et al. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf 2006 Jul; 15 (7): 435-43
84. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006 Apr 17; 97 Suppl. 8A: 61C-8C
85. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 Apr 8; 350 (15): 1495-504
86. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary artery disease. N Engl J Med 2005 Apr 7; 352 (14): 1425-35
87. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study. A randomized controlled trial. JAMA 2005 Nov 16; 294 (19): 2437-45
88. Koren MJ, Hunninghake DB, on behalf of the ALLIANCE investigatorsClinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease managment clinics: the ALLIANCE study. J Am Coll Cardiol 2004 Nov 2; 44 (9): 1772-9
89. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004 Aug 4; 44 (3): 720-32
90. Davis PH, Dawson JD, Riley WA, et al. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine study. Circulation 2001 Dec 4; 104: 2815-9
91. Oren A, Vos LE, Uiterwaal CSPM, et al. Cardiovascular risk factors and increased carotid intima-media thickness in healthy young adults: the Atherosclerosis Risk in Young Adults (ARYA) study. Arch Intern Med 2003 Aug 11-25; 163: 1787-92
92. Espeland MA, O'Leary DH, Terry JG, et al. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005 Mar 10; 6: 3
93. Schuster H. The GALAXY program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007 Mar; 5 (2): 177-93
94. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation 2004 Aug 31; 110 (9): 1061-8
95. Jensen LO, Thayssen P, Pedersen KE, et al. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 2004 Jul 20; 110 (3): 265-70
96. Blumenthal RS, Kapur NK. Can a potent statin actually regress coronary atherosclerosis? JAMA 2006 Apr 5; 295 (13): 1583-4
97. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004 Mar 3; 291 (9): 1071-80
98. AstraZeneca. First head to head study comparing Crestor™ and Lipitor® effects on the treatment of atherosclerosis [media release]. Available from URL: http://www.astrazeneca.com [Accessed 2008 Jan 24]
99. Takayama T, Hiro T, Yamagishi M, et al. Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects). Circ J 2007 Feb; 71 (2): 271-5
100. Ridker PM, on behalf of the JUPITER study group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003 Nov 11; 108 (19): 2292-7
101. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007 Nov 29; 357 (22): 2248-61
102. Fellström B, Zannad F, Schmeider R, et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005 May 23; 6: 9
103. McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006 Apr 17; 97 (8A Suppl.): 89C-94C
104. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007 Mar 1; 99 (5): 673-80